Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CNSP | US
-0.12
-4.86%
Healthcare
Biotechnology
30/06/2024
24/04/2026
2.35
2.34
2.43
2.26
CNS Pharmaceuticals Inc. a clinical pharmaceutical company engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals Inc. Reata Pharmaceuticals Inc. Pomeranian Medical University and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston Texas.
View LessLow Debt to Equity (< 0.25)
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
103.9%1 month
88.0%3 months
85.8%6 months
83.1%-
-
4.57
-0.03
0.05
0.40
-
-
-15.98M
75.54M
75.54M
-
-
-
-
-1.02K
0.44
2.11
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.99
Range1M
0.99
Range3M
4.64
Rel. volume
0.23
Price X volume
19.58K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Gossamer Bio Inc | GOSS | Biotechnology | 0.3627 | 82.05M | -2.92% | n/a | 243.93% |
| CRDF | CRDF | Biotechnology | 1.72 | 80.07M | 2.99% | n/a | 3.52% |
| iShares MSCI Brazil ETF USD Acc | CSBR | Biotechnology | 5.865 | 79.73M | -2.90% | n/a | -2140.66% |
| vTv Therapeutics Inc | VTVT | Biotechnology | 32.76 | 79.70M | -6.00% | n/a | 1.55% |
| Oncolytics Biotech Inc. (USA) | ONCY | Biotechnology | 1.03 | 79.16M | -5.50% | n/a | 0.00% |
| Cassava Sciences Inc | SAVA | Biotechnology | 1.615 | 77.48M | -2.71% | n/a | 0.00% |
| Equillium Inc | EQ | Biotechnology | 2.16 | 76.52M | -0.46% | n/a | 2.71% |
| Fortress Biotech Inc | FBIOP | Biotechnology | 14.25 | 76.49M | 6.26% | n/a | 494.61% |
| XBiotech Inc | XBIT | Biotechnology | 2.51 | 76.46M | -0.79% | n/a | 5.08% |
| Pliant Therapeutics Inc. | PLRX | Biotechnology | 1.24 | 75.39M | -1.59% | n/a | 15.34% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.765 | 73.67M | 1.69% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.9 | 70.43M | 6.56% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.77 | 33.16M | -2.81% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.40 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.57 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 85.77 | 72.80 | Par |
| Debt to Equity | -0.03 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 75.54M | 3.66B | Emerging |